OR WAIT null SECS
April 24, 2023
The Supreme Court’s action leaves open the prospect of further rulings that could undermine FDA’s approval process.
April 18, 2023
Bob Girton, partner at Edgewater, discusses best practices for how pharma manufactures should incorporate sustainability into their operations.
AbbVie’s RINVOQ has received European Commission approval for the treatment of moderately to severely active Crohn’s disease.
Gamida Cell’s therapy is meant to reduce the risk of infection following stem cell transplantation.
April 14, 2023
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
April 11, 2023
A document signed by members of more than 400 companies and investment firms decries the decision made by a federal judge concerning mifepristone, a medication used in abortions.
April 10, 2023
Will court challenges to FDA’s oversight authority open the door for multiple lawsuits to block agency decisions on all sides?
April 07, 2023
The agency is dealing with high demand for staff because of a surge in the development of cell and gene therapies.
FDA aims to address mounting criticisms of its accelerated approval pathway.
April 05, 2023
Change management is central to the evolution of quality control laboratories, but what factors can maximize patient outcomes?